

The Nomination Committee proposes new election of Anna Tenstam as ordinary Board member of Peptonic Medical

Stockholm, June 22, 2020. - Peptonic Medical AB (publ) ("The Company" or "Peptonic") - today announces that the Nomination Committee proposes that Anna Tenstam be elected to the Board. Furthermore, Hans von Celsing, Leni Ekendahl and Marianne Östlund are re-elected as members with Hans von Celsing as chairman. Arne Ferstad has declined re-election. The meeting will be held on June 30 in Stockholm.

The Nomination Committee proposes that the members receive SEK 75,000 in remuneration per year and that the Chairman receive SEK 150,000.

The Nomination Committee has been appointed on the basis of proposals from the largest shareholders, who together represent 14.4% of the votes in the Company. The nomination committee included Richard Bagge, Håkan Wallin and Hans von Celsing, with Richard Bagge as convener.

For more information, please contact;

Johan Inborr, CEO

Mobile: +46 708 853 893

E-mail: johan.inborr@peptonicmedical.se

This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 22th June 2020.

About Anna Tenstam

During her 30+ years in the Life-Science industry, she has held senior positions companies, both listed and so-called startups. These companies have been active in pharmaceuticals, medical technology, aesthetic medicine and diagnostics.

In her positions as CEO / Chairman in, among others, the USA, Israel and Sweden, she has been responsible for 50 to about 500 people with significant turnover. She has also founded several companies that she has developed and operated from start to exit.

Anna has acquired a global outlook and a broad perspective on developing companies in different cultures with strong growth, especially in women's health where she is involved in various networks. She has also launched consumer brands, which is especially valuable to Peptonic Medical, whose current portfolio requires a deep understanding of it in combination with medical technology products.

Anna has experience in various board positions since 2004 from companies based in the US, Sweden, Israel and the UK. Anna looks forward to contributing to Peptonic Medical's international success.

PEPTONIC

m e d i c a l

Current ongoing commitment;

- Agamé Beauty, Chairman of the Board
- Optomed Plc, Board Member
- Sue Ellen Investments, Chairman of the Board
- Expomind, Chairman of the Board

About VagiVital®

VagiVital® is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.

VagiVital® was launched in Sweden as a non-prescription self-care product in July 2018 (see www.vagivital.com).

About Peptonic Medical

Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.

VagiVital® is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.

Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (www.spotlightstockmarket.se, ticker: PMED) in Stockholm, Sweden.

For more information: www.peptonicmedical.com